During his keynote address at the Genetics Society of America: Model Organisms to Human Biology meeting in Boston this week, National Institute of General Medical Sciences director Jeremy Berg spoke about advances in pharmacogenomics related to warfarin dosing, the recent NIH-wide changes to grant applications, and NIGMS genetics and genomics resources for those who study model organisms, "from A to Z — from Arabidopsis to zebrafish." Berg also spoke about how investigators who use model organisms in their work might be most likely to receive NIGMS funding for their work.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.